Global Liver Cancer Diagnostics Market - Industry Trends and Forecast to 2030
The global liver cancer diagnostics market is projected to register a substantial CAGR of 6.5% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation
Global Liver Cancer Diagnostics Market, By Test Type (Imaging, Biopsy, Genomic Test, and Others), Cancer Stages (Stage 0, Stage I , Stage II, Stage III, and Stage IV), Cancer Type (Primary Liver Cancer and Secondary Liver Cancer), Product (Platform-Based Products, Instrument Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), Gender (Female and Male), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland and the rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, and the rest of Asia-Pacific, South Africa, Saudi Arabia, Egypt, Israel and the Rest of Middle East and Africa, Brazil, Argentina, and the Rest of South America) - Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the global liver cancer diagnostics market are:
• Rise in prevalence and incidence of liver cancer in the world
• Increase in awareness about the liver cancer diagnostics
Market Players
Some of the major players operating in the global liver cancer diagnostics market are:
• F. Hoffmann-La Roche Ltd.
• Koninklijke Philips N.V.
• Thermo Fisher Scientific Inc.
• BD
• Siemens Healthcare GmbH
• Agilent Technologies, Inc.
• Illumina, Inc.
• QIAGEN
• FUJIFILM Corporation
• Sysmex Corporation AB
• Scitex Pte Ltd. (Subsidiary of Danaher.)
• Epigenomics AG
• Tebubio
• Fujirebio
• Diagnostic Biosystems Inc.
• Q-LINE BIOTECH PVT LTD.
• MOLGEN
• BIOCEPT, INC.
• Boditech Med Inc.
• Elabscience Biotechnology Inc.
• Hipro Biotechnology Co., Ltd.
• Altogen Biosystems
• Tosoh India Pvt. Ltd.
• ABK Biomedical Inc.
• Diazyme Laboratories, Inc.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.
- 1 Introduction
- 1.1 Objectives Of The Study
- 1.2 Market Definition
- 1.3 Overview Of The Global Liver Cancer Diagnostics Market
- 1.4 Currency And Pricing
- 1.5 Limitations
- 1.6 Markets Covered
- 2 Market Segmentation
- 2.1 Markets Covered
- 2.2 Geographical Scope
- 2.3 Years Considered For The Study
- 2.4 Dbmr Tripod Data Validation Model
- 2.5 Primary Interviews With Key Opinion Leaders
- 2.6 Multivariate Modelling
- 2.7 Market Application Coverage Grid
- 2.8 Test Type Lifeline Curve
- 2.9 Dbmr Market Position Grid
- 2.10 Vendor Share Analysis
- 2.11 Secondary Sources
- 2.12 Assumptions
- 3 Executive Summary
- 4 Premium Insights
- 4.1 Pestle Analysis
- 4.2 Porter Analysis
- 4.3 Epidemiology
- 5 Global Liver Cancer Diagnostics Market, Regulations
- 6 Industry Insights
- 7 Market Overview
- 7.1 Drivers
- 7.1.1 Unmet Need For Non-invasive, Accurate, And Reliable Diagnostic Tests For Earlier Cancer Detection
- 7.1.2 Increasing Early Diagnosis Of Liver Cancer
- 7.1.3 Increasing Cases Of Liver Cancer
- 7.1.4 Rise In Diagnostic Product Approvals
- 7.2 Restraints
- 7.2.1 Barriers To Liver Cancer Diagnosis And Poor Prognosis
- 7.2.2 High False-positives And Poor Sensitivity Of Liver Cancer Diagnosis
- 7.3 Opportunities
- 7.3.1 Increasing Awareness Towards Liver Cancer
- 7.3.2 Government Initiatives Toward Liver Cancer Diagnostics
- 7.3.3 Growing Demand For Better Quality Healthcare
- 7.4 Challenges
- 7.4.1 Strict Regulations For The Approval Of Liver Cancer Diagnostic Products
- 7.4.2 Lack Of Skilled And Certified Expertise
- 8 Global Liver Cancer Diagnostics Market, By Test Type
- 8.1 Overview
- 8.2 Imaging Test
- 8.2.1 Magnetic Resonance Imaging (Mri)
- 8.2.1.1 Mr Angiography (Mra)
- 8.2.1.2 Mr Cholangiopancreatography
- 8.2.2 Computed Tomography
- 8.2.3 Positron Emission Tomography
- 8.2.4 Ultrasound
- 8.2.5 Others
- 8.3 Genomic Test
- 8.4 Biopsy
- 8.4.1 Fine Needle Aspiration Biopsy
- 8.4.2 Core Needle Biopsy
- 8.4.3 Laparoscopy
- 8.5 Others
- 9 Global Liver Cancer Diagnostics Market, By Cancer Stage
- 9.1 Overview
- 9.2 Stage Iii
- 9.3 Stage Ii
- 9.4 Stage Iv
- 9.5 Stage I
- 9.6 Stage 0
- 10 Global Liver Cancer Diagnostics Market, By Cancer Type
- 10.1 Overview
- 10.2 Secondary Liver Cancer
- 10.2.1 Hemangioma
- 10.2.2 Hepatic Adenoma
- 10.2.3 Focal Nodular Hyperplasia
- 10.3 Primary Liver Cancer
- 10.3.1 Hepatocellular Carcinoma (Hcc)
- 10.3.2 Intrahepatic Cholangiocarcinoma (Bile Duct Cancer)
- 10.3.3 Angiosarcoma Hemangiosarcoma
- 10.3.4 Hepatoblastoma
- 11 Global Liver Cancer Diagnostics Market, By Product
- 11.1 Overview
- 11.2 Platform Based Products
- 11.2.1 Next Generation Sequencing
- 11.2.2 Microarrays
- 11.2.3 Pcr
- 11.2.4 Others
- 11.3 Instrument Based Products
- 11.3.1 Imaging
- 11.3.2 Biopsy
- 11.4 Kits And Reagents
- 11.4.1 Elisa Test Kits
- 11.4.2 Cassette Test Kits
- 11.4.3 Others
- 11.5 Other Consumables
- 12 Global Liver Cancer Diagnostics Market, By Application
- 12.1 Overview
- 12.2 Screening
- 12.2.1 Platform Based Products
- 12.2.2 Instrument Based Products
- 12.2.3 Kits And Reagents
- 12.2.4 Other Consumables
- 12.3 Diagnostic And Predictive
- 12.3.1 Platform Based Products
- 12.3.2 Instrument Based Products
- 12.3.3 Kits And Reagents
- 12.3.4 Other Consumables
- 12.4 Prognostic
- 12.4.1 Platform Based Products
- 12.4.2 Instrument Based Products
- 12.4.3 Kits And Reagents
- 12.4.4 Other Consumables
- 12.5 Research
- 12.5.1 Platform Based Products
- 12.5.2 Instrument Based Products
- 12.5.3 Kits And Reagents
- 12.5.4 Other Consumables
- 13 Global Liver Cancer Diagnostics Market, By Technology
- 13.1 Overview
- 13.2 Fluorescent In Situ Hybridization
- 13.3 Next Generation Sequencing
- 13.4 Fluorimmunoassay
- 13.5 Comparative Genomic Hybridization
- 13.6 Immunohistochemical
- 13.7 Others
- 14 Global Liver Cancer Diagnostics Market, By Gender
- 14.1 Overview
- 14.2 Male
- 14.3 Female
- 15 Global Liver Cancer Diagnostics Market, By End User
- 15.1 Overview
- 15.2 Hospitals
- 15.3 Diagnostic Centers
- 15.4 Cancer Research Centers
- 15.5 Ambulatory Surgical Centers
- 15.6 Academic Institutes
- 15.7 Others
- 16 Global Liver Cancer Diagnostics Market, By Distribution Channel
- 16.1 Overview
- 16.2 Direct Tender
- 16.3 Retail Sales
- 16.4 Others
- 17 Global Liver Cancer Diagnostics Market, By Region
- 17.1 Overview
- 17.2 North America
- 17.2.1 U.S.
- 17.2.2 Canada
- 17.2.3 Mexico
- 17.3 Europe
- 17.3.1 Germany
- 17.3.2 France
- 17.3.3 Russia
- 17.3.4 Italy
- 17.3.5 U.K.
- 17.3.6 Spain
- 17.3.7 Turkey
- 17.3.8 Netherlands
- 17.3.9 Belgium
- 17.3.10 Switzerland
- 17.3.11 Rest Of Europe
- 17.4 Asia-pacific
- 17.4.1 China
- 17.4.2 India
- 17.4.3 Japan
- 17.4.4 Indonesia
- 17.4.5 Philippines
- 17.4.6 Thailand
- 17.4.7 Australia
- 17.4.8 Malaysia
- 17.4.9 South Korea
- 17.4.10 Singapore
- 17.4.11 Vietnam
- 17.4.12 Rest Of Asia-pacific
- 17.5 South America
- 17.5.1 Brazil
- 17.5.2 Argentina
- 17.5.3 Rest Of South America
- 17.6 Middle East And Africa
- 17.6.1 South Africa
- 17.6.2 Saudi Arabia
- 17.6.3 U.A.E.
- 17.6.4 Egypt
- 17.6.5 Israel
- 17.6.6 Rest Of Middle East And Africa
- 18 Global Liver Cancer Diagnostics Market, Company Landscape
- 18.1 Company Share Analysis: Global
- 18.2 Company Share Analysis: North America
- 18.3 Company Share Analysis: Europe
- 18.4 Company Share Analysis: Asia-pacific
- 19 Swot Analysis
- 20 Company Profile
- 20.1 F. Hoffmann-la Roche Ltd.
- 20.1.1 Company Snapshot
- 20.1.2 Revenue Analysis
- 20.1.3 Company Share Analysis
- 20.1.4 Product Portfolio
- 20.1.5 Recent Development
- 20.2 Koninlijke Philips N.V.
- 20.2.1 Company Snapshot
- 20.2.2 Revenue Analysis
- 20.2.3 Company Share Analysis
- 20.2.4 Product Portfolio
- 20.2.5 Recent Development
- 20.3 Thermo Fisher Scientific Inc.
- 20.3.1 Company Snapshot
- 20.3.2 Revenue Analysis
- 20.3.3 Company Share Analysis
- 20.3.4 Product Portfolio
- 20.3.5 Recent Development
- 20.4 Bd
- 20.4.1 Company Snapshot
- 20.4.2 Revenue Analysis
- 20.4.3 Company Share Analysis
- 20.4.4 Product Portfolio
- 20.4.5 Recent Developments
- 20.5 Siemens Healthcare Gmbh
- 20.5.1 Company Snapshot
- 20.5.2 Revenue Analysis
- 20.5.3 Company Share Analysis
- 20.5.4 Product Portfolio
- 20.5.5 Recent Development
- 20.6 Agilent Technologies, Inc.
- 20.6.1 Company Snapshot
- 20.6.2 Revenue Analysis
- 20.6.3 Product Portfolio
- 20.6.4 Recent Developments
- 20.7 Abk Biomedical Inc.
- 20.7.1 Company Snapshot
- 20.7.2 Product Portfolio
- 20.7.3 Recent Development
- 20.8 Ab Sciex Pte Ltd. (Subsidiary Of Danaher.)
- 20.8.1 Company Snapshot
- 20.8.2 Revenue Analysis
- 20.8.3 Product Portfolio
- 20.8.4 Recent Development
- 20.9 Altogen Biosystems
- 20.9.1 Company Snapshot
- 20.9.2 Product Portfolio
- 20.9.3 Recent Development
- 20.10 Biocept, Inc.
- 20.10.1 Company Snapshot
- 20.10.2 Revenue Analysis
- 20.10.3 Product Portfolio
- 20.10.4 Recent Development
- 20.11 Boditech Med Inc.
- 20.11.1 Company Snapshot
- 20.11.2 Product Portfolio
- 20.11.3 Recent Developments
- 20.12 Diagnostic Biosystems Inc.
- 20.12.1 Company Snapshot
- 20.12.2 Product Portfolio
- 20.12.3 Recent Development 492
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook